BEGIN:VCALENDAR
PRODID:-//Microsoft Corporation//OutlookMIMEDIR//EN
VERSION:2.0
X-WR-TIMEZONE:America/New_York
CALSCALE:GREGORIAN
METHOD:PUBLISH
CLASS:PUBLIC
BEGIN:VTIMEZONE
TZID:America/New_York
LAST-MODIFIED:20260306T231828Z
TZURL:https://www.tzurl.org/zoneinfo-outlook/America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
TZNAME:EDT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZNAME:EST
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York;VALUE=DATE:20241127
DTEND;TZID=America/New_York;VALUE=DATE:20241128
DTSTAMP:20260511T094441Z
UID:{A892927B-E98B-4307-97D425D8BE114F4C}
LOCATION:Zoom meeting
SUMMARY:Using Peptide-Drug Conjugates (PDCs) for the Precise Treatment of Pulmonary Fibrosis
DESCRIPTION:Dr. Kelly and her colleagues synthesized a panel of PDCs aiming at the precise treatment of pulmonary fibrosis, where nintedanib - a potent kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis - and a peptidomimetic targeting αVβ6 integrin - which is a receptor overexpressed in fibrotic tissues - are connected by different linkers. Given the promising in vitro results of one synthesized PDC, the in vivo antifibrotic activity is currently under evaluation in mice models of pulmonary fibrosis.\n
 \n
 Register at https://www.bocsci.com/holding-hands-using-peptide-drug-conjugates-pdcs-for-the-precise-treatment-of-pulmonary-fibrosis.html
PRIORITY:1
END:VEVENT
END:VCALENDAR